4D Molecular Therapeutics (NASDAQ:FDMT) Reaches New 12-Month High – What’s Next?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $15.03 and last traded at $14.55, with a volume of 3444983 shares trading hands. The stock had previously closed at $12.19.

Analyst Upgrades and Downgrades

FDMT has been the subject of several research analyst reports. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $29.62.

4D Molecular Therapeutics Price Performance

The stock has a 50 day simple moving average of $11.33 and a two-hundred day simple moving average of $10.03. The firm has a market cap of $925.82 million, a PE ratio of -6.37 and a beta of 2.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. Sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Insider Activity at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider owned 8,617 shares in the company, valued at approximately $103,404. This represents a 53.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David Kirn sold 12,415 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total transaction of $124,770.75. Following the sale, the insider directly owned 871,737 shares in the company, valued at $8,760,956.85. The trade was a 1.40% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 200,496 shares of company stock worth $2,240,244. Insiders own 7.90% of the company’s stock.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FDMT. AQR Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics in the first quarter worth about $46,000. Millennium Management LLC raised its holdings in 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after purchasing an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics in the 1st quarter worth about $39,000. American Century Companies Inc. boosted its position in 4D Molecular Therapeutics by 11.5% during the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock worth $181,000 after purchasing an additional 5,026 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in 4D Molecular Therapeutics by 11.7% during the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after purchasing an additional 2,284 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.